Long antibody HCDR3s from HIV-naïve donors presented on a PG9 neutralizing antibody background mediate HIV neutralization

Identification of Common Features in Prototype Broadly Neutralizing Antibodies to HIV Envelope V2 Apex to Facilitate Vaccine Design

(2015) Raiees Andrabi et al.   IMMUNITY

Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies

(2014) Nicole A. Doria-Rose et al.   NATURE

Prevalence of broadly neutralizing antibody responses during chronic HIV-1 infection

(2013) Peter Hraber et al.   AIDS

Broadly Neutralizing Antiviral Antibodies

(2013) Davide Corti et al.   Annual Review of Immunology

Impact of new sequencing technologies on studies of the human B cell repertoire

(2013) Jessica A Finn et al.   CURRENT OPINION IN IMMUNOLOGY

Neutralizing antibodies to HIV-1 induced by immunization

(2013) Laura E. McCoy et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Structural basis for diverse N-glycan recognition by HIV-1–neutralizing V1–V2–directed antibody PG16

(2013) Marie Pancera et al.   NATURE STRUCTURAL & MOLECULAR BIOLOGY

Mapping the Journey to an HIV Vaccine

(2013) Margaret Ackerman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Asymmetric recognition of the HIV-1 trimer by broadly neutralizing antibody PG9

(2013) Jean-Philippe Julien et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

A Blueprint for HIV Vaccine Discovery

(2012) Dennis R. Burton et al.   Cell Host & Microbe

Human Antibodies that Neutralize HIV-1: Identification, Structures, and B Cell Ontogenies

(2012) Peter D. Kwong et al.   IMMUNITY

HIV therapy by a combination of broadly neutralizing antibodies in humanized mice

(2012) Florian Klein et al.   NATURE

Human Peripheral Blood Antibodies with Long HCDR3s Are Established Primarily at Original Recombination Using a Limited Subset of Germline Genes

(2012) Bryan S. Briney et al.   PLoS One

Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9

(2011) Jason S. McLellan et al.   NATURE

Computed structures of point deletion mutants and their enzymatic activities

(2011) Monica Berrondo et al.   PROTEINS-STRUCTURE FUNCTION AND BIOINFORMATICS

Characteristics of the Earliest Cross-Neutralizing Antibody Response to HIV-1

(2011) Iliyana Mikell et al.   PLoS Pathogens

Neutralizing Antibodies and Control of HIV: Moves and Countermoves

(2011) Ann J. Hessell et al.   Current HIV/AIDS Reports

Crystal Structure of PG16 and Chimeric Dissection with Somatically Related PG9: Structure-Function Analysis of Two Quaternary-Specific Antibodies That Effectively Neutralize HIV-1

(2010) M. Pancera et al.   JOURNAL OF VIROLOGY

Variable Loop Glycan Dependency of the Broad and Potent HIV-1-Neutralizing Antibodies PG9 and PG16

(2010) Katie J. Doores et al.   JOURNAL OF VIROLOGY

Structure and function of broadly reactive antibody PG16 reveal an H3 subdomain that mediates potent neutralization of HIV-1

(2010) R. Pejchal et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Envelope glycans of immunodeficiency virions are almost entirely oligomannose antigens

(2010) K. J. Doores et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Broadly Neutralizing Monoclonal Antibodies 2F5 and 4E10 Directed against the Human Immunodeficiency Virus Type 1 gp41 Membrane-Proximal External Region Protect against Mucosal Challenge by Simian-Human Immunodeficiency Virus SHIVBa-L

(2009) A. J. Hessell et al.   JOURNAL OF VIROLOGY

Human Immunodeficiency Virus Type 1 Elite Neutralizers: Individuals with Broad and Potent Neutralizing Activity Identified by Using a High-Throughput Neutralization Assay together with an Analytical Selection Algorithm

(2009) M. D. Simek et al.   JOURNAL OF VIROLOGY

Effective, low-titer antibody protection against low-dose repeated mucosal SHIV challenge in macaques

(2009) Ann J Hessell et al.   NATURE MEDICINE

Broad and Potent Neutralizing Antibodies from an African Donor Reveal a New HIV-1 Vaccine Target

(2009) L. M. Walker et al.   SCIENCE

Broadly Neutralizing Human Anti-HIV Antibody 2G12 Is Effective in Protection against Mucosal SHIV Challenge Even at Low Serum Neutralizing Titers

(2009) Ann J. Hessell et al.   PLoS Pathogens